此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

VitaFlow LIBERTY 欧洲

VitaFlow Liberty™ 经导管主动脉瓣系统上市后临床随访研究

This is a prospective, single-arm, multi-center, observational, post-market clinical investigation to document the clinical safety and performance of MicroPort CardioFlow VitaFlow Liberty™ Transcatheter Aortic Valve System in the routine practice for the treatment of severe aortic valve stenosis. The primary endpoint is the composite rate of all-cause mortality and stroke with disability at 12 months.

Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.

研究概览

研究类型

观察性的

注册 (估计的)

222

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Castel Volturno、意大利
      • Pisa、意大利
        • 招聘中
        • Ospedale Cisanello
        • 接触:
      • Potenza、意大利
        • 招聘中
        • Azienda Ospedaliera Regionale -S.Carlo
        • 接触:
      • Galway、爱尔兰
        • 招聘中
        • Galway University Hospital
        • 接触:
          • Darren Mylotte, MD
      • Lucerne、瑞士
        • 招聘中
        • Luzerner Kantonsspital | Herzzentrum
        • 接触:
          • Dr.Stefan Toggweiler
          • 电话号码:0412051111
          • 邮箱:ifo@luks.ch
      • Carnaxide、葡萄牙
        • 招聘中
        • Hospital de Santa Cruz
        • 接触:
      • A Coruña、西班牙
        • 招聘中
        • Hospital Universitario de a Coruna
        • 接触:
      • Madrid、西班牙
      • Valladolid、西班牙

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with symptomatic, severe calcified aortic stenosis who are at high surgical risk.

描述

Inclusion Criteria:

  1. Subjects of age≥ 18 years
  2. Subjects with severe, symptomatic, calcific aortic stenosis who are considered at high risk for surgical aortic valve replacement (AVR).
  3. Subject can understand the purpose of the clinical investigation, has signed voluntarily the informed consent form and is agreeing to the scheduled follow up requirements.

Exclusion Criteria:

  1. Pre-existing mechanical heart valve in aortic position
  2. A known hypersensitivity or contraindication to all anticoagulation /antiplatelet regimens (or inability to be anticoagulated for the index procedure), to nickel or titanium, to nitinol, to dairy products, to polyethylene terephthalate (PET) or contrast media
  3. Ongoing sepsis, including active endocarditis
  4. Anatomically not suitable for the VitaFlow Liberty TAV system
  5. LVEF<20%
  6. Estimated life expectancy of less than 12 months
  7. Any medical, social or psychological condition that in the opinion of the Heart Team precludes the subject from receiving transcatheter aortic valve replacement
  8. Currently participating in another drug or device trial (excluding registries) for which the primary endpoint has not been assessed
  9. Inability to comply with the clinical investigation follow-up or other clinical investigation requirements
  10. Patients temporally unable to provide written informed consent (e. g. unconscious emergency patients)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
单臂临床研究

Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System.

Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Composite rate of all-cause mortality and stroke with disability
大体时间:12 months post procedure

Composite rate of all-cause mortality and stroke with disability

12 months post procedure

次要结果测量

结果测量
措施说明
大体时间
Safety outcomes defined by VARC3
大体时间:30 days, 12 months, and 2-5 years post procedure

Rate of all-cause mortality, myocardial infarction, stroke, implanted related new and/or worsen conduction disturbances and arrhythmias, new permanent pacemaker implantation, procedure-related or valve-related hospitalization defined by VARC 3.

30 days, 12 months, and 2-5 years post procedure
Safety outcomes defined by VARC3
大体时间:30 days and 12 months post procedure

Rate of type 2-4 bleeding, major vascular and access-related complications, acute kidney injury (stage 2-4) defined by VARC 3

30 days and 12 months post procedure
Safety outcomes defined by VARC3
大体时间:acute procedure (within 24 hours)

Rate of other acute procedural and technical valve related complications: conversion to surgery; unplanned use of mechanical circulatory support; implantation of multiple (>1) transcatheter valves during the index hospitalization; valve mal-position

acute procedure (within 24 hours)
Device success
大体时间:30 days post implantation

Device success defined by VARC 3

30 days post implantation
Device early safety
大体时间:30 days post implantation

Device early safety defined by VARC 3

30 days post implantation
Bioprosthesis haemodynamic function
大体时间:Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

Bioprosthesis haemodynamic function (assessed by echocardiography) including effective orifice area (cm2).

Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
Bioprosthesis haemodynamic function
大体时间:Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

Bioprosthesis haemodynamic function (assessed by echocardiography) including mean transvalvular gradient (mmHg).

Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
Bioprosthesis haemodynamic function
大体时间:Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation

Bioprosthesis haemodynamic function (assessed by echocardiography) including aortic regurgitation (paravalvular, central and total).

Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
Bioprosthetic valve dysfunction
大体时间:12 months and 2-5 years post procedure

Moderate or severe haemodynamic valve deterioration defined by VARC3

12 months and 2-5 years post procedure
Bioprosthetic valve dysfunction
大体时间:12 months and 2-5 years post procedure

Bioprosthetic valve failure defined by VARC3

12 months and 2-5 years post procedure
Bioprosthetic valve dysfunction
大体时间:12 months and 2-5 years post procedure

Clinically significant valve thrombosis defined by VARC3

12 months and 2-5 years post procedure
NYHA Classification
大体时间:From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure

Changes in cardiac function at discharge, 30 days and 12 months and 2-5 years post implantation according to the NYHA Classification Scheme compared to baseline

From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure
Rate of Alwide Plus Balloon Catheter pre-dilation success
大体时间:During procedure

Defined as successful access, delivery and dilation the aortic valve, and retrieval for the AlwideTM Plus balloon catheter

During procedure
Alwide Plus Balloon Catheter related adverse-event
大体时间:Discharge
Discharge
Predictors for the permanent pacemaker implantation
大体时间:Baseline or intraprocedure

Including but not limited to pre-existing conduction disturbance, implant depth, LVOT calcium volume , post-dilatation

Baseline or intraprocedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Darren Mylotte, MD、Galway University Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月6日

初级完成 (估计的)

2028年6月6日

研究完成 (估计的)

2033年6月1日

研究注册日期

首次提交

2024年7月21日

首先提交符合 QC 标准的

2024年7月30日

首次发布 (实际的)

2024年8月2日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2025年12月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅